The development of AML in patients with IDH1 mutations is often associated with abnormally elevated 2-HG levels [10], and accumulated 2-HG occupies the active site of α-KG-dependent dioxygenase and competitively inhibits its activity. This evidence concerns the gene IDH1 and acute myeloid leukemia.